BRPI0513423A - derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes - Google Patents
derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetesInfo
- Publication number
- BRPI0513423A BRPI0513423A BRPI0513423-4A BRPI0513423A BRPI0513423A BR PI0513423 A BRPI0513423 A BR PI0513423A BR PI0513423 A BRPI0513423 A BR PI0513423A BR PI0513423 A BRPI0513423 A BR PI0513423A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- blood sugar
- treatment
- aryl
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
DERIVADOS DE SALICILTIAZOL SUBSTITUìDOS COM DIFENILAMINA E COMPOSTOS RELACIONADOS COMO INIBIDORES DE FOSFATASE DE FOSFOTIROSINA 1B (PTP1B), PARA UTILIZAçãO COM SUBSTáNCIAS ATIVAS REDUTORAS DE AçúCAR NO SANGUE, PARA TRATAMENTO DE DIABETES. A presente invenção refere-se a compostos que desenvolvem um efeito terapêutico para diminuir o açúcar do sangue. Os compostos são particularmente apropriados para prevenção e tratamento de diabetes mellitus. A invenção refere-se, portanto, a compostos da fórmula (I), na qual significam: R1, R2, R3, R4, R5, independentemente um do outro,H, F,CL,Br,I,OH,CF~ 3~, NO~ 2~ ,CN, OCF~ 3~, O-(C~ 1~-C~ 6~)-alquila, O-(C~ 1~-C~ 4~)-alcóxi-(C~ 1~-C~ 4~)-alquila, S-(C~ 1~-C~ 6~)-alquila, (C~ 1~-C~ 6~)-alquila, (C~ 2~-C~ 6~)-alquenila, (C~ 3~-C~ 8~)-cicloalquila, O-(C~ 3~-C~ 8~)-cicloaquila, (C~ 3~-C~ 8~)-cicloalquia, (C~ 3~-C~ 8~)-cicloalquenila, O-(C~ 3~-C~ 8~)-cicloalquenila, (C~ 2~-C~ 6~)-alquinila, arila, O-aril (C~ 1~-C~ 8~)-alquileno-arila, O-(C~ 1-C~ 8~)-alquileno-arila, S-arila, CO-NH(C~ 1~-C~ 6~)-alquila, N(C~ 1~-C~ 6~)-alquil)2, NH-SO~ 2~-CH3, SO~ 2~-CH~ 3~, COOH, COO-(C~ 1~-C~ 6~)-alquila, CO-N((C~ 1~-C~ 6~)-alquil)~ 2~; R6: H, (C~ 1~-C~ 6~)-alquila; A: uma ligação, -CH~ 2~-, -NH-, -CH~ 2~-O-, -S-, -CH~ 2~-CH~ 2~-, -CH(CH~ 3~)-; B: NH, NH(C~ 1~-C~ 4~)-alquila, NH(CO); D: fenila, heterociclo; bem comoos sais fisiologicamente compatíves dos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004034697A DE102004034697A1 (de) | 2004-07-17 | 2004-07-17 | Mit Diphenylamin oder Diphenylaminderivaten substituierte Salicylthiazole, Verfahren zu deren Herstellung und deren Verwendung |
| PCT/EP2005/007151 WO2006007959A1 (de) | 2004-07-17 | 2005-07-02 | Diphenylaminsubstituierte salicylthiazolderivate und verwandte verbindungen als phosphotyrosinphosphatase 1b (ptp1b) hemmer zur verwendung als blutzuckersenkende wirkstoffe zur behandlung von diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513423A true BRPI0513423A (pt) | 2008-05-06 |
Family
ID=34971604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513423-4A BRPI0513423A (pt) | 2004-07-17 | 2005-07-02 | derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7741491B2 (pt) |
| EP (1) | EP1771426B1 (pt) |
| JP (1) | JP2008506643A (pt) |
| KR (1) | KR20070043787A (pt) |
| CN (1) | CN100582098C (pt) |
| AR (1) | AR049588A1 (pt) |
| AT (1) | ATE381551T1 (pt) |
| AU (1) | AU2005263418A1 (pt) |
| BR (1) | BRPI0513423A (pt) |
| CA (1) | CA2574162A1 (pt) |
| DE (2) | DE102004034697A1 (pt) |
| DK (1) | DK1771426T3 (pt) |
| ES (1) | ES2296199T3 (pt) |
| HK (1) | HK1104534A1 (pt) |
| IL (1) | IL180570A0 (pt) |
| MX (1) | MXPA06014443A (pt) |
| PE (1) | PE20060554A1 (pt) |
| PT (1) | PT1771426E (pt) |
| TW (1) | TW200616985A (pt) |
| UY (1) | UY29020A1 (pt) |
| WO (1) | WO2006007959A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001074793A2 (en) * | 2000-04-03 | 2001-10-11 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
| JP2005509616A (ja) * | 2001-10-16 | 2005-04-14 | センジェント・セラピューティクス・インク | チロシンホスファターゼに対する有機硫黄阻害剤 |
| US7163952B2 (en) * | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| EP1510207A4 (en) * | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | THERAPEUTIC MEDICAMENT AGAINST DIABETES |
-
2004
- 2004-07-17 DE DE102004034697A patent/DE102004034697A1/de not_active Withdrawn
-
2005
- 2005-07-02 DK DK05756578T patent/DK1771426T3/da active
- 2005-07-02 MX MXPA06014443A patent/MXPA06014443A/es active IP Right Grant
- 2005-07-02 BR BRPI0513423-4A patent/BRPI0513423A/pt not_active IP Right Cessation
- 2005-07-02 JP JP2007520705A patent/JP2008506643A/ja not_active Abandoned
- 2005-07-02 CN CN200580024146A patent/CN100582098C/zh not_active Expired - Fee Related
- 2005-07-02 PT PT05756578T patent/PT1771426E/pt unknown
- 2005-07-02 AT AT05756578T patent/ATE381551T1/de not_active IP Right Cessation
- 2005-07-02 AU AU2005263418A patent/AU2005263418A1/en not_active Abandoned
- 2005-07-02 CA CA002574162A patent/CA2574162A1/en not_active Abandoned
- 2005-07-02 EP EP05756578A patent/EP1771426B1/de not_active Not-in-force
- 2005-07-02 DE DE502005002310T patent/DE502005002310D1/de active Active
- 2005-07-02 ES ES05756578T patent/ES2296199T3/es active Active
- 2005-07-02 KR KR1020077001132A patent/KR20070043787A/ko not_active Application Discontinuation
- 2005-07-02 WO PCT/EP2005/007151 patent/WO2006007959A1/de active IP Right Grant
- 2005-07-11 PE PE2005000803A patent/PE20060554A1/es not_active Application Discontinuation
- 2005-07-14 AR ARP050102922A patent/AR049588A1/es not_active Application Discontinuation
- 2005-07-14 TW TW094123824A patent/TW200616985A/zh unknown
- 2005-07-15 UY UY29020A patent/UY29020A1/es unknown
-
2006
- 2006-12-12 US US11/609,463 patent/US7741491B2/en not_active Expired - Fee Related
-
2007
- 2007-01-04 IL IL180570A patent/IL180570A0/en unknown
- 2007-09-05 HK HK07109657.8A patent/HK1104534A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1771426E (pt) | 2008-01-31 |
| WO2006007959A1 (de) | 2006-01-26 |
| ATE381551T1 (de) | 2008-01-15 |
| CN1989116A (zh) | 2007-06-27 |
| HK1104534A1 (en) | 2008-01-18 |
| CN100582098C (zh) | 2010-01-20 |
| DE502005002310D1 (de) | 2008-01-31 |
| KR20070043787A (ko) | 2007-04-25 |
| AR049588A1 (es) | 2006-08-16 |
| TW200616985A (en) | 2006-06-01 |
| DK1771426T3 (da) | 2008-05-05 |
| DE102004034697A1 (de) | 2006-02-09 |
| AU2005263418A1 (en) | 2006-01-26 |
| MXPA06014443A (es) | 2007-03-21 |
| UY29020A1 (es) | 2006-02-24 |
| US20070191441A1 (en) | 2007-08-16 |
| ES2296199T3 (es) | 2008-04-16 |
| US7741491B2 (en) | 2010-06-22 |
| PE20060554A1 (es) | 2006-06-24 |
| IL180570A0 (en) | 2007-06-03 |
| CA2574162A1 (en) | 2006-01-26 |
| EP1771426B1 (de) | 2007-12-19 |
| EP1771426A1 (de) | 2007-04-11 |
| JP2008506643A (ja) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513423A (pt) | derivados de saliciltiazol substituìdos com difenilamina e compostos relacionados como inibidores de fosfatase de fosfotirosina 1b (ptp1b), para utilização como substáncias ativas redutoras de açúcar no sangue, para tratamento de diabetes | |
| EA200900066A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| BRPI0607031A2 (pt) | combinação sinergìstica de compostos ativos fungicidas | |
| AR042658A1 (es) | Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides | |
| HRP20010468B1 (en) | Azabicycloalkanes as ccr5 modulators | |
| WO2007006926A3 (fr) | Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
| UY30013A1 (es) | 5-aril isoxazolinas para controlar plagas de invertebrados | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| EA200800303A1 (ru) | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами | |
| ATE464895T1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen | |
| DE602006017543D1 (de) | Neue verbindungen | |
| NI201000022A (es) | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. | |
| ZA200602077B (en) | Combinations comprising alpha-2-delta ligands and serotonin/noradrenaline re-up-take inhibitors | |
| PE20080856A1 (es) | Inhibidores de metaloproteasas de matriz | |
| BRPI0415511A (pt) | derivados de n-[fenil (pirrolidina-2-il) metil] benzamida e da n-[(azepan-2-il) fenilmetil] benzamida, preparação dos mesmos e aplicação dos mesmos em terapia | |
| AR041299A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| JP2008506643A5 (ja) | 糖尿病の治療用の血糖値低下活性成分として使用するためのホスホチロシン・ホスファターゼ１ｂ(ｐｔｐ１ｂ)阻害剤としてのジフェニルアミン置換サリチルチアゾール誘導体及び関連化合物 | |
| EA200802403A1 (ru) | Азолилметилоксираны, их применение для борьбы с фитопатогенными грибами, а также содержащие их средства | |
| AR064307A1 (es) | Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion. | |
| RU2010128940A (ru) | Производные бензилфенилциклогексана и способы их применения | |
| WO2007120379A3 (en) | Sulfonanilide analogs as selective aromatase modulators | |
| AR074604A1 (es) | Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano. | |
| ATE512950T1 (de) | Neue cyclische verbindung mit 4- pyridylalkylthiogruppe mit darin eingeführtem (un)substituiertem amino | |
| CA2547591A1 (en) | Novel compounds and compositions as cathepsin inhibitors | |
| MY143953A (en) | 2,3,4,5-tetrahydrobenzo [f][1,4] oxazepine-5-carboxylic acid amide derivates as gamma-secretase inhibitors for the treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011. |